纯狼疮性膜性肾病的治疗反应结局与预测因素
这项法国25中心回顾性研究纳入194例活检证实的初发纯狼疮性膜性肾病患者,评估不同初始治疗策略的12个月肾脏缓解率。结果显示免疫抑制方案间12个月肾脏缓解率无显著差异,但抗U1RNP抗体与治疗失败独立相关,而肾外狼疮受累为保护因素;利妥昔单抗方案与更短疗程和节省激素相关。
要点
- 抗U1RNP抗体阳性者12个月治疗失败风险更高(调整OR 2.53)。
- 无肾外狼疮受累与治疗失败风险升高独立相关(调整OR 0.39)。
- 利妥昔单抗方案与更短治疗时长和节省糖皮质激素相关。
核心结论
- 初发纯狼疮性膜性肾病患者12个月肾脏缓解率在不同免疫抑制方案间无显著差异。
- 抗U1RNP抗体与治疗失败风险升高独立相关,而肾外狼疮受累与治疗失败风险降低独立相关。
- 基于抗CD20的策略可能是 promising 的治疗选择。
研究设计与样本
- 多中心回顾性研究,纳入法国25个中心2000至2020年间活检证实的初发纯狼疮性膜性肾病患者194例。
- 按初始治疗策略分组:支持治疗53例(27.3%),免疫抑制治疗141例(72.7%)。
- 免疫抑制治疗中,MMF方案54例(38.3%),利妥昔单抗方案26例(18.4%),其他方案61例(43.3%)。
- 肾脏缓解率依据2024年KDIGO指南定义,采用logistic回归分析12个月治疗失败相关因素。
主要发现
- 12个月完全肾脏缓解率:支持治疗36.7%,MMF 47.1%,利妥昔单抗64.0%,其他方案45.4%。
- 12个月完全或部分肾脏缓解率:支持治疗55.1%,MMF 60.8%,利妥昔单抗72.0%,其他方案54.5%。
- 多变量分析中,抗U1RNP抗体与治疗失败独立相关(调整OR 2.53;95%CI 1.35-4.70;P=0.004)。
- 肾外狼疮受累与治疗失败风险降低独立相关(调整OR 0.39;95%CI 0.19-0.73;P=0.004)。
- 利妥昔单抗方案与更短治疗时长和节省糖皮质激素显著相关。
关键数值与推荐
- 肾脏缓解率定义依据2024年KDIGO指南。
- 12个月完全肾脏缓解率利妥昔单抗组64.0%,MMF组47.1%,支持治疗组36.7%,其他方案组45.4%。
- 12个月完全或部分肾脏缓解率利妥昔单抗组72.0%,MMF组60.8%,支持治疗组55.1%,其他方案组54.5%。
临床怎么用
- 对初发纯狼疮性膜性肾病患者,可考虑利妥昔单抗为基础的方案,其与更短疗程和节省激素相关。
- 抗U1RNP抗体阳性提示治疗失败风险较高,需加强监测和随访。
- 无肾外狼疮受累的患者治疗失败风险亦较高,应予以关注。
局限性
- 回顾性研究设计可能存在选择偏倚和信息偏倚。
- 各组样本量不均衡,利妥昔单抗组仅26例。
- 12个月随访时间较短,缺乏长期肾脏结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The indications and modalities of therapeutic strategies for first-onset pure lupus membranous nephropathy (PLMN) remain poorly defined. We aimed to evaluate renal response rates across real-world treatment strategies and identify predictors of treatment response in PLMN. METHODS: We conducted a multicenter retrospective study in 25 French centers. Patients with biopsy-proven first-onset PLMN treated between 2000 and 2020 were included. Patients were classified according to their initial treatment strategy. Renal response rates were defined based on the 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Factors associated with treatment failure at 12 months were assessed using logistic regression. RESULTS: Among 194 patients with PLMN, 53 (27.3%) received supportive care only, and 141 (72.7%) received immunosuppressive therapy (54 [38.3%] received mycophenolate mofetil (MMF)-based regimens, 26 [18.4%] received rituximab [RTX]-based regimens, and 61 [43.3%] received other treatments). At 12 months, rates of complete renal response (CRR) and CRR or partial renal (PRR) were respectively, 36.7% and 55.1% with supportive care, 47.1% and 60.8% with MMF, 64.0% and 72.0% with RTX, and 45.4% and 54.5% with other regimens. In multivariable analysis, the presence of anti-U1-ribonucleoprotein (U1RNP) antibodies was independently associated with treatment failure (adjusted odds ratio [OR]: 2.53; 95% confidence interval [CI]: 1.35-4.70; P = 0.004), whereas extrarenal lupus involvement was protective (adjusted OR = 0.39; 95% CI: 0.19-0.73; P = 0.004). RTX-based regimens were significantly associated with shorter treatment duration and corticosteroid sparing. CONCLUSION: In patients with first-onset PLMN, 12-month renal response rates did not differ significantly among immunosuppressive regimens despite variation in treatment duration and steroid exposure. Anti-U1RNP antibodies and absence of extrarenal involvement were associated with a higher risk of treatment failure. Anti-CD20-based strategies may be a promising therapeutic approach.
引用
- Chevalier K, Brousse R, Karras A, et al. Outcomes and Predictors of Treatment Response in Patients With Pure Lupus Membranous Nephropathy. Kidney Int Rep. 2026. PMID: 42494786. doi:10.1016/j.ekir.2026.106678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。